» Articles » PMID: 14974743

Development of Acquired Drug Resistance in Recurrent Tuberculosis Patients with Various Previous Treatment Outcomes

Overview
Specialty Pulmonary Medicine
Date 2004 Feb 21
PMID 14974743
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Setting: Chiang Rai province, Northern Thailand.

Objective: To study the probability of acquiring drug resistance to isoniazid (H) and rifampicin (R) on recurrence after treatment success, default and failure, among sputum smear-positive pulmonary tuberculosis (TB) patients treated with standardised short-course chemotherapy.

Design: Retrospective analysis of registration records of TB patients from May 1996 to December 2000 in Chiang Rai, where routine drug susceptibility testing (DST) is conducted for surveillance purposes. Patients registered twice or more were examined.

Results: Of 59 cases treated with HRZE/HR who underwent DST at the time of registration, 31 were fully susceptible to H and R at first registration, of whom four acquired drug resistance to H or R. Of 13 cases resistant to H or R at first registration, 11 became multidrug-resistant (MDR). The remaining 15 patients were original MDR cases. Among 28 MDR or H- or R-resistant cases, six reverted from resistant to susceptible.

Discussion: A high proportion of patients with H- or R-resistant TB became MDR after treatment with 2HRZE/HR. Using this regimen, MDR may increase in a population with a high prevalence of H or R resistance. We are unable to explain why some drug-resistant cases became drug-susceptible. Further investigation is necessary.

Citing Articles

Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse.

Endsley J, Huante M, Naqvi K, Gelman B, Endsley M Retrovirology. 2021; 18(1):14.

PMID: 34134725 PMC: 8206883. DOI: 10.1186/s12977-021-00559-z.


The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.

Van Deun A, Decroo T, Maug A, Hossain M, Gumusboga M, Mulders W PLoS One. 2020; 15(5):e0233500.

PMID: 32421749 PMC: 7233532. DOI: 10.1371/journal.pone.0233500.


Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection.

Huante M, Saito T, Nusbaum R, Naqvi K, Chauhan S, Hunter R Front Cell Infect Microbiol. 2020; 10:150.

PMID: 32373548 PMC: 7176873. DOI: 10.3389/fcimb.2020.00150.


Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.

Ambreen A, Jamil M, Rahman M, Mustafa T BMC Infect Dis. 2019; 19(1):923.

PMID: 31666021 PMC: 6822412. DOI: 10.1186/s12879-019-4561-7.


Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman S, Alipanah N, Barry P, Brozek J, Cattamanchi A Clin Infect Dis. 2016; 63(7):e147-e195.

PMID: 27516382 PMC: 6590850. DOI: 10.1093/cid/ciw376.